Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for postinfectious cerebellitis.
6 publications have been identified in PubMed for postinfectious cerebellitis. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (33%), and Epidemiology / Natural History (17%).
Johnson VA (2026). [PMID: 42023770](https://pubmed.ncbi.nlm.nih.gov/42023770/). *JAAPA*. [Case Report / Case Series]
Zhao Q (2025). [PMID: 41321459](https://pubmed.ncbi.nlm.nih.gov/41321459/). *Frontiers in pediatrics*. [Epidemiology / Natural History]
Zhao W (2025). [PMID: 41469174](https://pubmed.ncbi.nlm.nih.gov/41469174/). *BMJ case reports*. [Case Report / Case Series]
Jones C (2025). [PMID: 41325013](https://pubmed.ncbi.nlm.nih.gov/41325013/). *Journal of child neurology*. [Review / Meta-Analysis]
Mitoma H (2024). [PMID: 39052041](https://pubmed.ncbi.nlm.nih.gov/39052041/). *Journal of neurology*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning postinfectious cerebellitis
Updated Apr 23, 2026
Recent research highlights the occurrence of cerebellitis and cytotoxic lesions of the corpus callosum following COVID-19 infection. This study adds to the understanding of neurological complications associated with the virus.